Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40662364.
- Also identified by DOI 10.1172/JCI191944 and PMC identifier 12259248.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Despite advances in multidisciplinary oncology care, curing patients diagnosed with pancreatic duct adenocarcinoma (PDAC) remains all too uncommon. In this Review, we discuss evolving concepts to guide the care of patients with operable PDAC, focusing on adjuvant and neoadjuvant systemic therapies, the ever-controversial topic of radiation therapy, and the emerging role of cancer vaccines. Given the promise of biomarkers to better predict therapeutic response, the development of KRAS inhibitors, our ability to deliver higher doses of radiation therapy more precisely and safely, and the technology to rapidly produce highly personalized cancer vaccines, there is reason to expect that the guidelines for the care of our patients with operable PDAC will change rapidly in the next few years.
Medical subject headings
- Pancreatic Neoplasms
- Neoadjuvant Therapy
- Carcinoma, Pancreatic Ductal
- Cancer Vaccines